Madrigal director John Reed reports no MDGL stake

MADRIGAL PHARMACEUTICALS, INC.

Rhea-AI Filing Summary

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an initial ownership report for John C. Reed, who is identified as a director of the company. This Form 3 does not list any stock or derivative holdings and reports no transactions. The filing also references an Exhibit 24 Power of Attorney authorizing filing actions.

Key Terms

Form 3, Power of Attorney, director

3 terms

Form 3 regulatory

"filed an initial ownership report for John C. Reed"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Power of Attorney regulatory

"The filing also references an Exhibit 24 Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

director financial

"John C. Reed, who is identified as a director of the company"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the MDGL Form 3 filing for John C. Reed report?

The Form 3 for MDGL reports that John C. Reed is a director of Madrigal Pharmaceuticals and currently discloses no reported holdings or transactions in the company’s securities.

Does John C. Reed report any MDGL share transactions in this Form 3?

No, the filing reports no transactions. The transaction summary shows 0 buy, 0 sell, and 0 acquire or dispose events, indicating this document is purely an initial ownership statement.

What role does John C. Reed have at Madrigal Pharmaceuticals (MDGL)?

John C. Reed is identified as a director of Madrigal Pharmaceuticals, Inc. The Form 3 shows he is not reported as an officer or 10% owner, focusing solely on his board role.

What is the significance of Exhibit 24 in the MDGL Form 3?

The remarks section notes “Exhibit 24: Power of Attorney.” This indicates a Power of Attorney authorizing someone to sign and submit SEC ownership filings on John C. Reed’s behalf for MDGL.

Does the MDGL Form 3 indicate any derivative securities for John C. Reed?

No, the derivativeSummary is empty, and holding entries are zero. This means the Form 3 reports no options, warrants, or other derivative positions for John C. Reed in MDGL at this time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:05 PM EDT Accepted by SEC EDGAR 08/18/2026 - 05:04 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

REED JOHN C

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

1001 CONSHOHOCKEN STATE ROAD SUITE 2-350

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2026

3. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24: Power of Attorney

No securities are beneficially owned.

	/s/ Mardi Dier, as Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)